AstraZeneca presented data from two phase 3 trials at the annual American Society for Clinical Oncology (ASCO) meeting. The first data presentation was for the…
Galapagos and Gilead have halted the phase 3 ISABELA program, consisting of two studies evaluating ziritaxestat in patients with idiopathic pulmonary fibrosis (IPF). The decision…
A group of Finish and American research study results show that COVID-19 outcome is mediated primarily through respiratory distress. Risk factors for severe COVID-19 have…
Amgen and AstraZeneca announced positive results from NAVIGATOR, a phase 3 trial evaluating tezepelumab versus placebo, both added to standard of care (SOC), in adults…
Pfizer presented data from a phase 3 trial of its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate in adults 18 years of age or older not…
Regeneron and Sanofi announced positive results from the phase 3 LIBERTY ASTHMA VOYAGE trial which evaluated Dupixent (dupilumab) in children aged 6 to 11 years with…
Corbus Pharmaceuticals announced topline results from its 28-week Phase 2b study (CF-002) of lenabasum in patients with cystic fibrosis (CF). Lenabasum did not reduce the…
AstraZeneca presented data from its ADAURA Phase III trial showing that Tagrisso (osimertinib) demonstrated clinically meaningful improvement in central nervous system disease-free survival (DFS) in…
UK-based, publicly traded Synairgen’s stock (LSE:SNG) price exploded recently after positive clinical trial results, while the company has to issue a clarification regarding their SNG001…
The government of the United Kingdom (UK) approved dexamethasone, a commonly prescribed steroid treatment, as a COVID-19 therapy thanks to the successful University of Oxford…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
